Search Results
Aug 22, 2026, 16:00 ET (NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm
NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.
More news about: Kessler Topaz Meltzer & Check, LLP
Aug 16, 2026, 16:58 ET Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.
More news about: Kessler Topaz Meltzer & Check, LLP
Aug 05, 2026, 04:28 ET ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
ALNY) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading
More news about: Schall, Brown & Schwartz LLP
May 28, 2026, 09:15 ET Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
landscape, Avaí Bio, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Beam Therapeutics Inc. (NASDAQ: BEAM), and Sana Biotechnology, Inc. (NASDAQ: SANA) collectively represent the breadth of where cell-based
More news about: USA News Group
Oct 13, 2025, 11:00 ET Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM Intelligence
Developments in the Market In August 2025, Roche and Alnylam (Nasdaq: ALNY) announced their decision to launch a Phase III cardiovascular outcomes trial (CVOT) to assess whether zilebesiran, an RNAi therapeutic, can reduce the
More news about: DataM Intelligence 4 Market Research LLP
Sep 18, 2025, 09:15 ET Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the
More news about: Illumina, Inc.